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ABSTRACT
Introduction: Ketogenic diet is a low carbohydrate diet, which can be used as a treatment for refractory childhood epilepsy. The first 
aim of this study was to evaluate its efficacy, in patients receiving ketogenic diet for at least three months, on epilepsy control, behaviour 
and awareness. The secondary aims were to evaluate the variation in the number of antiepileptic drugs, reasons for discontinuing the 
diet and adverse effects.
Material and Methods: Retrospective analysis of clinical records of patients who underwent ketogenic diet for refractory epilepsy, from 
October 2007 to January 2018, in a tertiary pediatric hospital. 
Results: In the twenty-nine eligible patients, the mean age of initiation was 7.9 years-old (+/– 5.6). Of those, 18 had a ≥ 50% reduc-
tion of seizure activity, 19 a marked behaviour improvement and 18 improved awareness. The median number of antiepileptic drugs 
remained equal for the 15 patients who completed 18 months of treatment (three drugs). The main reason for discontinuing ketogenic 
diet was a familiar decision. The main adverse effects were hypercholesterolemia (n = 23) and hypertriglyceridemia (n = 21).
Discussion: Results were comparable to those of other cohorts, namely age of initiation, proportion of patients completing ketogenic 
diet, most frequent reasons for stopping and significant improvement of alertness and behavior.
Conclusion: Beyond seizure control, patients experienced a marked improvement in behavior and awareness. It is necessary to de-
velop strategies to increase the adherence of families to the diet.
Keywords: Child; Diet, Ketogenic; Drug Resistant Epilepsy/diet therapy; Portugal
RESUMO
Introdução: A dieta cetogénica é uma dieta com baixo teor de hidratos de carbono, que pode ser usada no tratamento da epilepsia 
infantil refratária. O principal objetivo deste estudo foi avaliar a eficácia nos doentes que completaram pelo menos três meses de dieta, 
no que respeita ao controlo das crises, comportamento e estado de alerta. Foi também avaliada a variação do número de fármacos 
antiepiléticos, as razões de descontinuação e os efeitos secundários.
Material e Métodos: Análise retrospetiva dos processos clínicos dos doentes com epilepsia refratária sob dieta cetogénica, de outubro 
de 2007 a janeiro de 2018, num hospital pediátrico de nível 3. 
Resultados: Nos 29 doentes elegíveis, a média da idade de implementação foi 7,9 anos (+/– 5,6). Destes, 18 tiveram uma redução 
≥ 50% das crises, 19 tiveram uma melhoria marcada do comportamento e 18 do seu estado de alerta. Dos 15 que completaram 
18 meses, a mediana do número de fármacos antiepiléticos permaneceu idêntica à do início (três fármacos). A principal razão de 
descontinuação foi por decisão familiar. Os principais efeitos secundários foram a hipercolesterolémia (n = 23) e a hipertrigliceridémia 
(n = 21).
Discussão: Os resultados foram semelhantes aos obtidos noutras coortes, nomeadamente no que respeita à idade de início, à per-
centagem de doentes que completou a dieta, às razões da suspensão e à melhoria do comportamento e estado de alerta.
Conclusão: Para além do controlo das crises, os doentes tiveram uma marcada melhoria do seu comportamento e estado de alerta. 
É necessário desenvolver estratégias para aumentar a adesão das famílias à dieta.
Palavras-chave: Criança; Epilepsia Resistente a Medicamentos/dietoterapia; Portugal
INTRODUCTION
Refractory or pharmacoresistant epilepsy can be defined 
as epilepsy that does not respond to two or more antiepi-
leptic drugs and represents 20% to 30% of childhood epi-
lepsies. After a period of residual use due to the explosion 
of new antiepileptic drugs (AED), ketogenic diet (KD) was 
reborn as a useful treatment tool for these patients. Besides 
the indication for specific inborn errors of metabolism, there 
is growing evidence that KD therapies are useful not only in 
this subset of epilepsies but also in cancer, traumatic brain 
injury, Alzheimer and Parkinson diseases and autism spec-
trum disorders.1,2 
KD is a high-fat, low-carbohydrate diet, nowadays 
with different modalities like classic and modified KD and 
medium-chain triglycerides, low glycemic index and mod-
ified Atkins diets (the last two being more used in adults).3 
In refractory childhood epilepsy and epileptic encephalopa-
thy (EE), the classic KD has more evidence of efficacy but 
the others, less restrictive, are gaining space.4,5
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Figure 1 – Flow diagram of patients’ selection
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Although the exact mechanism of action is not com-
pletely clarified, KD seems to act through different and syn-
ergistic pathways involving neurotransmitters, ion channel 
regulation, bioenergetics and mitochondrial changes.6,7
There are recommendations from the International 
League Against Epilepsy (ILAE) and the International 
Ketogenic Diet Study Group, which allow the improvement 
and adaptation of local guidelines. Similar protocols make 
the results of KD therapy more comparable.8–10 Recently, a 
multidisciplinary group of experts published specific guide-
lines for infants, paying attention to the particular nutrition-
al and developmental needs of this age group.11 However, 
there is still lack of connection between the different cen-
tres, even within countries, and also of multicentre studies 
in order to define which epilepsy types would respond bet-
ter to KD.1,12 Other points of discussion are the minimum 
period of time required to expect a positive response to KD 
(although a three month period is somewhat consensual) 
and the appropriate time to carry out the diet’s weaning pro-
cess, since doing it at 18 or 24 months is not considered 
adequate by some centres. Besides, there are a few rand-
omized controlled trials in which one of the arms includes 
epileptic patients under KD.1,10,12–14
In this observational retrospective study, our aim was 
to evaluate the efficacy of KD therapies in childhood 
refractory epilepsy/EE, considering the protocol followed 
at our institution regarding seizure reduction, awareness 
and behavior improvement. Secondary objectives were to 
evaluate the main reasons for discontinuation, acute and 
chronic complications and the repercussion on patients’ 
AED schedule.
MATERIAL AND METHODS 
Subjects
This study was conducted in a tertiary Portuguese pedi-
atric hospital. Clinical charts from patients who begun KD 
between October 2007 and January 2018, were reviewed. 
Data were obtained until the end of April 2018. 
The authors have followed the protocols of their work 
centre on the publication of data. The data was anonymized 
and none of the authors had access to patient identification.
The study is being conducted in accordance with the 
Helsinki Declaration.
Inclusion criteria were: 1) EE and refractory epilepsy 
(patients who maintain seizures despite optimal treatment 
with two or more AED) and 2) accomplishment of at least 
three months of diet. 
Exclusion criteria were: 1) Diagnosed inherited metabol-
ic diseases and 2) loss of follow-up or lack of adherence to 
the diet after the first three months period.
Twenty-nine patients were eligible as depicted in Fig.1. 
Local KD protocol
Patients with refractory epilepsy, with recognized eti-
ology or epileptic syndrome, are proposed to KD by the 
Neuropediatrics Epilepsy team. A meeting at the Metabolic 
Disease unit is scheduled, in order to explain KD and eval-
uate the capacity and motivation of the family to follow it. 
A complete medical and nutritional assessment is done. 
Diagnostic tests are also performed: glucose, albumin and 
pre-albumin, calcium, zinc, selenium, magnesium, chloride, 
ammonium, transaminases, urea, creatinine, uric acid, cho-
lesterol, triglycerides, 25-OH-vitamine D, blood acylcarni-
tines profile, blood gases, urinalysis with calcium/creatinine 
urine ratio, and tetrapolar bioelectric impedance exam. In 
order to select the type and initial ratio of KD therapy to 
implement, age, type of feeding, needs and preferences of 
the child and its family are considered. Usually KD is imple-
mented in an inpatient setting, for three days, in a 2:1 to 3:1 
ratio of lipids to carbohydrates plus proteins, in grams, with 
a close monitoring of acute complications. During this stay, 
parents are instructed on how to use Keto Diet Calculator®, 
to prepare the meals and to monitor ketonemia, glycemia 
and ketonuria. Follow-up appointments are scheduled at 
the Metabolic Diseases unit at days 7 to 15 and months 1, 3, 
6, 12, 18 and 24. Medical, nutritional and analytical assess-
ments are made during outpatient visits, in order to assess 
efficacy and secondary effects. KD should be discontinued 
at 18 to 24 months if successful or at three months if unsuc-
cessful. Suspension is gradual in two to three months. More 
recently, patients have been called for a visit after the com-
plete weaning of the diet (end of the diet). 
Efficacy assessment
Data analysis is presented concerning:
1) Epileptic activity — based on patients’ diary (number 
43 patients initiated
Ketogenic Diet
37 patients
29 patients
6 patients with
Metabolic Disease
8 patients did not
complete 3 months or
had poor compliance
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Table 1 – Demographics and diet chronologies (n = 29)
No. or mean 
(+/– SD; min – max)¶
Male 17
Age of beginning (years old)
< 5
[5 – 10[
[10 – 15[
[15 – 20[
7.9 (+/– 5.6; 9M – 18)
11
8
5
5
Hospital beginning 
Days of hospitalization
25
3.5 (+/– 1.43; 2 – 7)
Ceased the diet
Duration (M)
18
18.2 (+/– 9.8; 3 – 36)
M: months; max: maximum; min: minimum; No.: number; SD: standard 
deviation
Table 2 – Clinical diagnosis and known aetiologies of the 29 patients
Clinical diagnosis No. (Total 29)
• Lennox-Gastaut syndrome
     Postinfectious 
     del 22q11.21 *
     Focal cortical dysplasia type II 
     Multifocal cortical dysplasia
     SYNGAP1 mutation *
     No defined etiology
9
3
1
1
1
1
2
• West syndrome 
     Perinatal stroke     
     MCD *
     PEHO syndrome *
     MAGI 2 mutation *
     Tetrasomy 15q
7
2
2
1
1
1
• Epilepsy with myoclonic-atonic seizures 4
• Ohtahara syndrome 
    Classic lissencephaly due to mutation 
    No defined etiology
2
1
1
• Myoclonic epilepsy in infancy 2
• Landau-Kleffner syndrome 1
• Dravet syndrome 1
• Focal epilepsy
     Tuberous sclerosis complex
1
1
• Generalized absence epilepsy 1
• FIRES * 1
*del: deletion; FIRES: febrile infection-related epilepsy syndrome; MAGI 2: 
membrane-associated Guanylate kinase Inverted 2; MCD: malformations 
of cortical development; PEHO: progressive encephalopathy with edema, 
hypsarrhythmia and optic atrophy; SYNGAP1: synaptic Ras GTPase 
activating protein 1.
and intensity of seizures throughout the KD) and in data 
obtained with awake and sleep electroencephalograms 
(6 months before and at 3, 6, 12, 18 and 24 months of KD). 
The outcome was classified in five groups: 100% seizure 
reduction or seizure free, from 90% to 99% seizure reduc-
tion, from 50% to 90% seizure reduction, less than 50% 
seizure reduction and no reduction. We defined efficacy in 
seizure control as a seizure reduction rate of 50% or higher, 
as reported by other groups14;
2) Behavior — a subjective measure, based in par-
ents and clinicians’ perception and information from school 
staff. The outcome was classified in three groups: marked 
improvement, moderate improvement and no improvement;
3) Awareness — equal to the previous item;
4) AED schedule — number of drugs at the beginning 
and at the end of KD of children who completed at least 
18 months of KD. 
Secondary effects
We searched for:
1) Acute effects, occurring in the first week of KD, name-
ly: vomiting, nausea, acidosis, hypoglycemia, fever, food 
refusal, lethargy and mood change;
2) Chronic effects, occurring after the first week of KD: 
hyperlipidaemia, failure to thrive, constipation, electrolytic 
imbalances, hyperuricemia, carnitine and vitamin deficien-
cies, hepatitis, anemia and chronic infections.
Reasons for discontinuation
We also looked at reasons of discontinuation.
Statistical analysis
Descriptive analysis was performed using the 14.2 
version of the STATA software (Copyright 1985–2015 
StataCorp LP). Due to the small sample size no tests were 
performed. 
RESULTS
Demographics and KD implementation
Twenty-nine patients were analyzed, correspond-
ing to 17 males and 12 females, with a mean age of 7.9 
years old at the beginning of KD (+/– 5.6 years old; range 
9 months – 18 years old) (Table 1). The majority (n = 25) 
began their diet as inpatients, after elective admissions 
for this purpose, with a mean of 3.5 days of hospitaliza-
tion (+/– 1.43 days; range 2 – 7). Three started KD as 
outpatients: one had a brother who had already received 
KD, one was the second time he was initiating KD and 
the third one due to family constraints. A 10-month female 
with febrile infection-related epilepsy (FIRES), started the 
KD in the Intensive Care unit, and was the only one who 
received ketogenic total parenteral nutrition. At discharge, 
21/25 (84%) were on a 2.5 – 3.0:1 ratio of fat to protein and 
carbohydrates KD, one was on a higher ratio and the other 
four on a less restrictive KD therapy. 
When the analysis was carried out, 18/29 (62.1%) had 
ceased the diet; the remaining eleven patients were still 
under KD. For those eighteen, the mean duration of the KD 
was 18.2 months (+/– 9.8 months; range 3 – 36). The reten-
tion rate at 12 months was 77.8% (n = 14) and at 18 months 
55.6% (n = 10). Those who stopped between 3 to 18 months, 
did it due to: family choice (n = 5) and inefficacy (n = 3).
Diagnosis
Clinical diagnoses according to the International League 
Against Epilepsy (ILAE) classification of epilepsies and epi-
leptic syndromes are listed in Table 2. The most common 
diagnoses were Lennox-Gastaut syndrome (n = 9) and 
West syndrome (n = 7). 
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Efficacy assessment
Concerning seizure control: four of the twenty-nine 
patients (13.8%) became seizure free, four (13.8%) had 
≥ 90% reduction and nine (31%) achieved a 50% – 90% 
decrease. In short, there was ≥ 50% seizure reduction 
in seventeen patients (58.6%). Regarding behavior and 
awareness, there was a marked improvement in eighteen 
(62.1%) and in nineteen (65.5%) patients, respectively. 
Ten patients (34.5%) completed the 18 months KD 
period: three became seizure-free, other five had a reduc-
tion > 50% of seizure activity, nine had a marked behavior 
improvement and five improved their awareness.
The effects of KD on seizure control, behavior and 
awareness according to the electroclinical syndrome are 
summarized in Table 3. 
In five patients with malformations of the cortical devel-
opment, a 50% – 90% reduction in seizure frequency 
was achieved in three and two showed no improvement. 
Regarding behavior and awareness there was a marked 
improvement in three. 
In those with a history of central nervous system infection 
(n = 3), there were distinct responses: two who had menin-
gococcal meningitis became seizure free, with a marked 
improvement in behavior and awareness; one with herpes 
simplex virus encephalitis had no seizure improvement and 
there was a moderate impact on behavior and awareness.
The two patients with vascular events of the central nerv-
ous system had a moderate to marked behavior improvement.
The case of tuberous sclerosis complex had < 50% sei-
zure reduction, with a moderate improvement on behavior 
and a marked effect on awareness. 
The response to KD according to genetic mutations and 
chromosome abnormalities, already identified, are repre-
sented in Table 4.
Looking at the fifteen patients who completed at least 
18 months of KD, for 4/15 (26.7%) there was a reduction 
of the number of AED (two with Lennox-Gastaut syndrome 
and two with epilepsy with myoclonic-atonic seizures), 
10/15 (66.7%) maintained the same number (four with 
Lennox-Gastaut syndrome, three with West syndrome, one 
with Ohtahara syndrome, one with Dravet syndrome and 
one with focal epilepsy) and in a case of Landau-Kleffner 
syndrome (6.7%), there was the need to add one more 
AED. The median number of AED at the beginning was 
three, just like at the end of treatment.
Adverse effects
Acute complications were documented in twenty-six 
of the twenty-nine patients. The most frequent were hypo-
glycemia and nausea/vomiting, reported in six and five 
patients, respectively. 
Chronic side effects were observed in all twenty-nine 
patients and were not responsible for diet discontinuation. 
Hypercholesterolemia presented in twenty-three (79.3%) 
and hypertriglyceridemia in twenty-one (72.4%) patients. 
Constipation was documented in nine (31%), being de novo 
in one patient. Anemia was detected in one patient and 
no cases of increased levels of hemoglobin, hematocrit or 
mean corpuscular volume were found. Pancreatitis, bone 
fractures and nephrolithiasis were not found. Other meta-
bolic imbalances occurred as depicted in Table 5. 
Of the eighteen patients who ceased KD, seven patients 
(38.9%) did a screening for persistent abnormal laboratory 
tests after the end of treatment: 6/7 had hypercholester-
olemia which disappeared in five, 5/7 had hypertriglyceri-
demia which disappeared in four and 4/7 had hyperuricemia 
which disappeared in all of them. 
DISCUSSION
The mean age of initiation of KD therapy, seven years-
old, was similar to what is described by other groups (who 
also follow the guidelines of the International Ketogenic Diet 
Study Group). This is understandable since KD is still not 
seen as a first line therapy for childhood epilepsy, and is 
Table 3 – Efficacy by electroclinical diagnosis (ILAE classification), in the 29 patients on KD for more than three months
Lennox-
Gastaut 
syndrome
(n = 9)
West
syndrome
(n = 7)
Epilepsy with 
myoclonic-
atonic
seizures
(n = 4)
Ohtahara 
syndrome
(n = 2)
Myoclonic 
epilepsy 
in infancy 
(n = 2)
Landau-
Kleffner 
syndrome 
(n = 1)
Dravet 
syndrome
(n = 1)
Tuberous 
sclerosis 
complex
(n = 1)
Gener-
alized 
absence 
epilepsy 
(n = 1)
FIRES† 
(n = 1)
Seizure 
reduction 
rate
100% 3 0 1 0 0 0 0 0 0 0
> 90% 1 1 1 0 0 1 0 0 0 0
50% – 90% 3 2 2 1 0 0 1 0 0 1
< 50% 1 2 0 0 1 0 0 1 0 0
0% 1 2 0 1 1 0 0 0 1 0
Improve-
ment in 
awareness
Marked 7 5 3 1 0 1 1 1 0 0
Moderate 1 1 1 0 2 0 0 0 1 1
None 1 1 0 1 0 0 0 0 0 0
Improve-
ment in 
behaviour
Marked 6 5 4 1 0 1 1 0 0 0
Moderate 2 0 0 0 2 0 0 1 1 1
None 1 2 0 1 0 0 0 0 0 0
†FIRES: febrile infection-related epilepsy syndrome
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only considered in cases of refractory epilepsy.5,12 Evidence 
of KD safety and efficacy in infants and younger children 
is growing, with the particularity of being better accepted 
before the introduction of solid food.11,15 In 2015, Dressler 
et al highlighted the efficacy of KD in infants with spasms, 
myoclonic astatic epilepsy and focal epilepsy.15,16
Like in most centers, the majority of our patients (25/29; 
86.2%) started KD as inpatients.10,12,17 This allowed not only 
to closely monitor for acute complications and its manage-
ment but also a fine tuning of KD, which explained why 
there were different diet ratios at discharge.
Recently attention has been paid to ketogenic parenteral 
nutrition. We had one patient with FIRES, which began KD 
in the Intensive Care Unit. There were no adverse events, 
as reported by Dressler et al.18 FIRES is a good candidate 
for KD, as reported by various authors.10,19–21
Regarding the length of KD therapy in our cohort, the 
median duration was close to the required minimum period 
of 18 months. Considering those who ceased KD (18/29; 
62.1%), the retention rate at 12 months was 77.8%. Ten 
children completed at least 18 months of KD, other eight 
stopped before completing the protocol. The rate of patients 
who completed the diet was similar to that described by 
Hallböök T et al, 55.6% vs 37.1%, and was higher than in 
the study reported by Vehmeijer FOL et al, (18.6%). The 
retention rate at 12 months was higher than in the study by 
Wijnen BFM et al (77.8% vs 54%).12,13,22
Familiar decision (n = 5) and inefficacy (n = 3) were the 
most frequent reasons for stopping KD. In the evaluation of KD 
candidates, focus on family motivation and capacity is man-
datory, since these are key conditions for diet compliance.
The time-consuming and effort-intensive characteris-
tics of the KD possibly explain the large drop-out rate in the 
study by Wijnen BFM et al, perhaps justifying the lack of 
effect of KD on quality of life.12–14,23
It would be important to have predictors of KD efficacy, 
so that we could prescribe it to those who would improve, as 
managing the diet is more time consuming than providing 
AEDs. Some researchers aimed to discover a link between 
etiology and epilepsy-type and response to KD, but until 
now they have not succeeded.24 Data obtained by Hallböök 
et al suggested a relationship between seizure frequency 
before initiation and response (the best responders were 
those without daily seizures); Vehmeijer’s group found that 
children with a successful response at three months were 
significantly more likely to achieve success at one month 
follow-up.13,23 Due to the limited dimension of our cohort, we 
cannot draw conclusions on the efficacy related to seizure 
reduction. However, we observed an important improve-
ment regarding alertness and behavior, as previously 
described by other authors.10,25–27 This is very important to 
caregivers as it strengthens the relationship with their child, 
enabling them to enjoy their relationship and, at the same 
time, keep them motivated to continue with KD. 
Table 4 – Efficacy by pathogenic mutations and chromosome abnormalities identified in seven of the 29 patients
SYNGAP1 
gene**
(n = 1)
SCN9A 
gene**
(n = 1)
TSC1 
gene**
(n = 1)
MAGI2 
gene**
(n = 1)
LIS
gene**
(n = 1)
Tetrasomy 
15q
(n = 1)
del 
22q11.21**
(n = 1)
Seizure 
reduction rate
100% X
> 90% X
50% – 90% X X X
< 50% X X
0%
Improvement in 
awareness
Marked X X X X X
Moderate X X
None
Improvement in 
behaviour
Marked X X X X
Moderate X X
None X
**del: deletion; LIS: lissencephaly; MAGI2: membrane-associated Guanylate kinase inverted 2; SCN9A: sodium voltage-gated channel alpha subunit 9 
(FIRES); TSC1: tuberous sclerosis 1; SYNGAP1: synaptic Ras GTPase activating protein 1.
Table 5 – Acute and chronic adverse effects of KD (n = 29)
Acute adverse effects No. (Total 26) ¶¶
Hypoglycemia  
Nausea / vomiting 
Lethargy 
Acidosis 
Food refusal
6
5
4
3
2
Chronic adverse effects No. (Total 29) ¶¶
Hypercholesterolemia
Hypertriglyceridemia 
Hypercalciuria  
Hyperuricemia 
Hyperphosphatemia 
Constipation / de novo 
Urine crystals  
Hypercalcemia  
Carnitine deficit 
Hypomagnesemia  
Zinc deficit 
Vitamin D deficit  
Calcium deficit 
Hypophosphatemia  
Anemia
23
21
14
12
10
9/1
9
7
6
5
3
2
2
2
1
¶¶No.: number
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In seventeen out of twenty-nine patients (58.6%) there 
was a significant seizure decrease (≥ 50%). Both retrospec-
tive and prospective studies have shown that more than half 
of the patients treated with KD therapy achieved more than 
50% seizure reduction.1,5,22,27 
When searching in the literature for efficacy by etiol-
ogy, rewarding results were obtained with KD in Dravet 
syndrome (with no different response regarding the type of 
mutation as reported by Dressler et al), epilepsy with myo-
clonic-atonic seizures, tuberous sclerosis complex, but also 
in Otahara syndrome, Lennox-Gastaut syndrome and West 
syndrome.10,28–31 
The median number of AED remained equal at the end 
of KD (3 AED). Pasca et al highlighted the need for specific 
indications on how to cope with AED during KD, although 
different studies showed that the co-administration of AED 
and KD seems to be safe.33,34 Studies comparing KD with 
long-term AED  are also needed.
The most common acute complications in our cohort 
were hypoglycemia (6/26; 23.1%) and nausea / vomiting 
(5/26; 19.2%). In the Abigail Lin et al study, these were also 
the most reported adverse acute effects (representing 28% 
and 42%, respectively). Hypoglycemia was rapidly and eas-
ily corrected in all patients in both cohorts.17
Dyslipidemia has been widely described as a frequent 
adverse effect of KD. Different studies have demonstrated 
the reversibility of these changes. Özdemir et al looked at the 
elastic properties of the aorta and carotid arteries of patients 
that received at least 12 months of KD and found no chang-
es. Even in other studies where atheroma was described it 
disappeared after KD discontinuation. Dyslipidemia associ-
ated with KD also appears to have no disturbing effects on 
ventricular function.35,36 Not all our patients underwent lab-
oratory tests after completing treatment. In those who did, 
cholesterol levels normalized in 5/6 and the triglycerides in 
4/5. It would be reassuring to monitor the disappearance of 
dyslipidemia through laboratory tests at three months after 
KD cessation. 
It is important to reinforce that, as described in litera-
ture, the adverse effects were not the main reason for 
discontinuation.37
None of our patients experienced pancreatitis, hepati-
tis or bone fractures. In other series, nephrolithiasis was a 
cause for KD discontinuation.1,9 Although fourteen patients 
in our cohort presented hypercalciuria and nine had crystals 
in urine, none had to stop the diet.
In agreement with other studies, in our series, multiple 
mineral and vitamin imbalances were detected, as seen in 
Table 4.1,38 They were addressed with appropriate supple-
mentation and had no clinical consequences.
Contrary to the recently published study by Kose et al, 
we did not find increased levels of hemoglobin, hematocrit, 
mean corpuscular volume and vitamin B12. We have only 
detected anemia in one patient.39
In 2009, Marçal M et al published a study on the effects 
of KD in twenty-seven Portuguese epileptic children. This 
study, which was until now the only paper about KD use in 
Portuguese children, showed favorable results in refractory 
epilepsy.40 By that time, the protocol in use was different, 
for example, the patients had to undergo an initial fasting 
period that is no longer used. They also evaluated behavior 
and cognition with similar results. We felt it was important to 
report our results, since they may be helpful to inform treat-
ment of these rare conditions where there are few patients 
described, namely with similar kinds of mutations.
The main limitations of the present study are its retro-
spective nature and the reduced number of cases of each 
etiology. The fact that two of the main variables analyzed 
are subjective (awareness and behavior) can also be con-
sidered as a limitation. 
CONCLUSION
KD is a therapeutic weapon for refractory childhood 
epilepsy/EE and should be considered earlier in the treat-
ment schedule of selected epileptic syndromes as Lennox-
Gastaut syndrome and West syndrome. The effects of KD 
are not limited to seizure control, and also include improve-
ment of behavior and awareness. 
Some aspects of our daily practice may be improved like 
the choice of KD therapy that better fits a specific patient 
and family and the way KD is introduced to families, which 
needs to be more appealing in order to increase adherence.
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